CC
MRNA icon

Capital Counsel’s Moderna MRNA Stock Holding History

Capital Counsel’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Sell
6,172
-30
-0.5% -$1.55K 0.02% 43
2026
Q1 		$315K Buy
+6,202
New +$289K 0.01% 50
2025
Q2 		– Sell
-8,727
Closed -$247K – 60
2025
Q1 		$247K Sell
8,727
-13
-0.1% -$461 0.01% 47
2024
Q4 		$363K Sell
8,740
-330
-4% -$15.8K 0.02% 43
2024
Q3 		$606K Hold
9,070
– – 0.03% 36
2024
Q2 		$1.08M Sell
9,070
-900
-9% -$114K 0.05% 30
2024
Q1 		$1.06M Sell
9,970
-431
-4% -$43.4K 0.05% 31
2023
Q4 		$1.03M Sell
10,401
-170
-2% -$14.3K 0.05% 32
2023
Q3 		$1.09M Buy
10,571
+2,353
+29% +$262K 0.06% 29
2023
Q2 		$998K Hold
8,218
– – 0.06% 30
2023
Q1 		$1.26M Buy
8,218
+450
+6% +$74.2K 0.07% 29
2022
Q4 		$1.4M Buy
7,768
+21
+0.3% +$3.43K 0.09% 26
2022
Q3 		$916K Buy
7,747
+30
+0.4% +$4.55K 0.06% 30
2022
Q2 		$1.1M Buy
7,717
+24
+0.3% +$3.43K 0.07% 29
2022
Q1 		$1.32M Sell
7,693
-6
-0.1% -$1.01K 0.06% 28
2021
Q4 		$1.96M Sell
7,699
-91
-1% -$26.6K 0.08% 24
2021
Q3 		$3M Sell
7,790
-50
-0.6% -$18.4K 0.15% 21
2021
Q2 		$1.84M Sell
7,840
-180
-2% -$32.2K 0.09% 26
2021
Q1 		$1.05M Buy
+8,020
New +$1.16M 0.06% 32

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Capital Counsel's MRNA Position: Q2 2026 in Review

Capital Counsel reduced its Moderna (MRNA) stake by 0.48% in Q2 2026, selling an estimated $1.55K and leaving 6,172 shares worth $432K. The position accounts for 0.02% of the portfolio, ranked #43.

Capital Counsel first reported a position in MRNA in Q1 2021 and has held it in 19 quarters since. The position peaked at $3M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Capital Counsel held 6,172 shares of Moderna worth $432K as of Q2 2026.
  • Capital Counsel sold 30 Moderna shares in Q2 2026, an estimated $1.55K.
  • Moderna made up 0.02% of Capital Counsel's portfolio in Q2 2026, its #43 holding.
  • Capital Counsel first reported a position in Moderna in Q1 2021 and has held it in 19 quarters since.
  • Capital Counsel's Moderna position peaked at $3M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Capital Counsel's 13F filing for Q2 2026, filed 12 Aug 2026.